Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
53
-
Total 13F shares, excl. options
-
21.1M
-
Shares change
-
-2.5M
-
Total reported value, excl. options
-
$44M
-
Value change
-
-$10.5M
-
Put/Call ratio
-
1.65
-
Number of buys
-
32
-
Number of sells
-
-39
-
Price
-
$2.08
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q2 2019
80 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q2 2019.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 53 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21.1M shares
of 193M outstanding shares and own 10.92% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (5.53M shares), PRIMECAP MANAGEMENT CO/CA/ (4.04M shares), LADENBURG THALMANN FINANCIAL SERVICES INC. (1.77M shares), MORGAN STANLEY (1.61M shares), BANK OF MONTREAL /CAN/ (1.05M shares), Hudson Bay Capital Management LP (885K shares), BlackRock Inc. (658K shares), JENNISON ASSOCIATES LLC (628K shares), Foresite Capital Management IV, LLC (608K shares), and MILLENNIUM MANAGEMENT LLC (521K shares).
This table shows the top 53 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.